Enanta Pharmaceuticals Inc (ENTA)

[dewophile]

The odd thing is that there were several failures in this space of drugs that clearly have good antiviral activity. The analyst just didn’t push back. I’m fact zelicapavir itself failed in the standard risk RSVP study. The most notable failure was Lumicitabine which JNJ picked up from Alios which had challenge data on par with zelicapavir , was a replication inhibitor too (Nuke targeting polymerase), and failed to show an effect in their peds study. The drug was terminated for safety but there is a paper summarizing the clinical data among those that did get enrolled.